TenderlineUK
Procurement Intelligence
Official OCDSSearch
Find a TenderCancelledProcurement termination notice
Published 8 Dec 2025, 15:19 GMT

Official UK procurement notice

ALMAC - active and placebo capsule manufacture for the LAMDARCT Clinical Trial ​

Authority: Belfast Health & Social Care Trust (Central government)

Direct award
Sectors: Medical Devices & Pharma (33) Delivery: Northern Ireland (UKN)
Budget not disclosedValue not published
Submission deadline 11 Aug 2025

What is being bought

Published requirement description

This procurement if for active and placebo capsule manufacture for the LAMDARCT Clinical Trial .

The lotProcurement structure

single lot · no lot value published
Lot #1Lot 1Awarded
Delivery: Northern Ireland
33600000 Pharmaceutical products

Procedure terms & legal framework

From the official record
Procedure method
Direct award
Legal basis
UKPGA · 2023/54 Procurement Act 2023
Notice status
Cancelled
Procurement threshold
Unspecified in notice
Regulatory regime
Standard
Commercial structure
Stand-alone contract (no framework)
Competition type
Competitive procedure
GPA / WTO covered
Unspecified in notice
Recurring procurement
No (one-off requirement)
First published
8 Dec 2025, 15:19 GMT
Last source update
8 Dec 2025, 15:19 GMT
Authority reference
DAC
Latest notice
Procurement termination notice (UK12)
Delivery area
Northern Ireland (UKN)
Official registry OCID
ocds-h6vhtk-058571
Why no open competition
Prototypes Development
Published justification
Schedule 5, (2) The public contract concerns the production of a prototype, or supply of other novel goods or services, for the purpose of (c) other research, experiment, study or development. Age-related macular degeneration (AMD) is a leading cause of visual loss. There are two main forms of AMD: dry and wet. The current wet AMD treatment is intravitreal antiVEGF injections, repeated every 4-12 weeks. Due to the more…cost of the medication, the route and frequency of administration, this treatment is a significant burden on the NHS budget.An additional treatment option for wet AMD is L-dopa. L-dopa is a widely available drug (used in treatment of Parkinson's), typically in the form of Carbidopa-L-Dopa. It is taken as an oral tablet and is significantly cheaper than the antiVEGF injections. The study will be a placebo-controlled clinical trial. Eligible patients will be randomised to receive either 100mg L-DOPA+25mg carbidopa or placebo twice a day, for 24 months, in addition to the current standard of care to determine if this is a more cost-effective and easier-to-administer treatment regime than the current standard of care. ​ To 'blind' this clinical trial (to reduce bias) requires the development and manufacture of over encapsulated 100mg L-DOPA+25mg carbidopa tablets and development and manufacture of matching placebo capsules. The expertise required to develop and manufacture these capsules in the quantity required for this trial requires outsourcing to a manufacturer licensed by the MHRA possessing the necessary technical expertise.

How it was run

Submission deadline
—

Timeline

2 published dates · Europe/London
  1. Standstill ends
    20 Aug 2025, 23:59 BST
  2. Notice published292 days ago
    8 Dec 2025, 15:19 GMT

Commercial outcome & contract awards

Published awards, contracts and bid statistics — not a forecast
Awards 1
Awarded value £416,7891 award exc. VAT
Contracts signed 1
Awarded toValueDateStatus
ALMAC CLINICAL SERVICES LIMITEDActive and placebo capsule manufacture for the LAMDARCT Clinical Trial1 Nov 2025 — 1 Nov 2029£416,78911 Aug 2025Awarded

Contracts

  • Contract 1 · ALMAC CLINICAL SERVICES LIMITED

    Signed
    date not published
    Value
    —
    Status
    cancelled (5 Dec 2025) — Start date, value and scope have changed, a UK5 and UK6 will be published for a new procurement.

Notice history

7 events · 3 releases on Find a Tender · since 11 Aug 2025
  1. Procurement termination notice published
    8 Dec 2025, 15:19 GMTUK12
  2. Status changed
    8 Dec 2025, 15:19 GMT
  3. Procurement method changed
    8 Dec 2025, 15:19 GMT
  4. Buyer details updated
    8 Dec 2025, 15:19 GMT
  5. Contract signature expected
    1 Oct 2025, 23:59 BSTscheduled
  6. Contract award notice published
    11 Aug 2025, 16:30 BSTUK6
  7. Transparency notice published
    11 Aug 2025, 16:13 BSTUK5

Contracting authority & participating public bodies

Belfast Health & Social Care Trust

Contracting authorityPublic authority - central governmentNorthern Irish devolved regulations apply GB-PPON: PLQJ-5727-JCLR Trust Headquarters, 2nd Floor, Non Clinical Support Building, Royal Victoria Hospital, Belfast, Northern Ireland, BT12 6BA [email protected]

Bidders & participating suppliers

1 commercial party on the notice

Official documents & specifications (4)

Official links; attachments are not copied

Tender pack and attachments

  • Conflict of interest declarationtenderConflict of interest declarationNot published

Notices published for this procedure